Zenith Epigenetics Corp.

Albany Molecular Research, Inc.

Kinentia Biosciences LLC

Bristol-myers Squibb Compnay

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Michigan

Science Applications International Corporation

Amr Technology, Inc.

David John Fairfax

Gregory Scott Martin

John Frederick Quinn

Peter Ronald Young

Bryan Cordell Duffy

Gregory Steven Wagner

Shuang Liu

Zhicai Yang

James Aaron Balog

John Michael McCall

Graham Johnson

Hai-Yun Xiao

Mark E Salvati

William Bert Geiss

Keith Douglas Barnes

Russell Joseph Deorazio

Matthew Robert Johnson

Van-Duc Le

Dmytro O Tymoshenko

Lisa Helen Peterson

Jill Heemskerk

Manzer Durrani

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Biaryl derivatives as bromodomain inhibitors

Cyclic amines as bromodomain inhibitors

4-Fluoro-4-phenylpiperidin-1-yl &#x3bc; antagonists of general structure as well as pharmaceutical compositions comprising compounds of formula I, are disclosed. These compounds and compositions are useful as treatments of conditions or diseases associated with binding opioid receptors including pain, obesity, hyperalgesia, inflammation, osteoarthritis, drug addiction, and cancer. These compounds and compositions are also useful as treatments for tardive dyskinesia.

4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators

This invention describes substituted pyrazole derivatives of Formula I and methods of making and using the compounds. These compounds have utility in the treatment of conditions or diseases in which modification of the activity of ERK would have a positive therapeutic outcome, for instance various cancers, psoriasis and actinic keratosis.

Pyrazole derivatives as ERK inhibitors

Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift. 

Compounds for the treatment of spinal muscular atrophy and other uses

Compounds of formulae I and II: are disclosed as 5-HTinhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.

Benzoxazole carboxamides for treating CINV and IBS-D

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.

Soluble 1,4 benzodiazepine compounds and stable salts thereof

Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.

Tricycloundecane compounds useful as modulators of nuclear hormone receptor function

Growing community of inventors

Slingerlands, NY, United States of America

David John Fairfax